Download presentation
Presentation is loading. Please wait.
Published byHannah Simpson Modified over 6 years ago
1
Arteriovenous fistula patency in the 3 years following vonapanitase and placebo treatment
Eric K. Peden, MD, Timothy P. O'Connor, MD, Barry J. Browne, MD, Bradley S. Dixon, MD, Andres S. Schanzer, MD, Stephen C. Jensik, MD, Albert D. Sam, MD, Steven K. Burke, MD Journal of Vascular Surgery Volume 65, Issue 4, Pages (April 2017) DOI: /j.jvs Copyright © 2016 The Authors Terms and Conditions
2
Fig 1 Flow of patients through the study. AVF, Arteriovenous fistula; FU, follow-up; PD, peritoneal dialysis. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
3
Fig 2 Arteriovenous fistula (AVF) primary patency: red, vonapanitase 30 μg; green, vonapanitase 10 μg; black, placebo. A, All AVFs. B, All AVFs excluding patency loss events due to angioplasty of cephalic arch or central vein stenosis. C, Radiocephalic AVFs. D, Brachiocephalic AVFs. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
4
Fig 3 Arteriovenous fistula (AVF) secondary patency: red, vonapanitase 30 μg; green, vonapanitase 10 μg; black, placebo. A, All AVFs. B, Radiocephalic AVFs. C, Brachiocephalic AVFs. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.